enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Buy” by Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has earned an average rating of “Buy” from the eleven research firms that are covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $29.78.

ENGN has been the topic of a number of research analyst reports. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. HC Wainwright started coverage on shares of enGene in a research note on Monday, December 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. Finally, Raymond James assumed coverage on enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company.

Institutional Trading of enGene

Several hedge funds have recently modified their holdings of the company. SR One Capital Management LP purchased a new position in shares of enGene in the 2nd quarter worth approximately $4,715,000. Logos Global Management LP grew its holdings in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares during the last quarter. Wolverine Asset Management LLC acquired a new position in shares of enGene during the third quarter worth $37,000. Point72 Asset Management L.P. lifted its holdings in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Down 6.1 %

ENGN stock opened at $7.49 on Tuesday. The firm has a fifty day moving average price of $7.64 and a 200 day moving average price of $7.64. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Sell-side analysts forecast that enGene will post -1.52 earnings per share for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.